Patent focus on antiparasitic agents: May - October 1999

Bibliography

• RIDLEY RG, HUDSON AT: Chemotherapy of malaria. Curr. Opin. Infec. Dis. (1998) 11:691–705.
   PubMed Web of Science ®Google Scholar
• ••A review detailing advances made since 1997 in malariachemotherapy.
   Google Scholar
• POSNER GH: Antimalarial peroxides in the qinghaosu (artemisinin) and yingzhaosu families. Exp. Opin. Thar. Patents (1998) 8(10:1487–1494.
   Google Scholar
• ••A review of scientific and patent literature on antimalarialperoxides up to mid-1998.
   Google Scholar
• JUNG M, LEE S: Stability of acetal and non-acetal-type analogs of artemisinin in simulated stomach acid. Bioorg. Med. Chem. Letts. (1998) 8:1003–1006.
   PubMed Web of Science ®Google Scholar
• LI Q-G, PEGGINS JO, FLECKENSTEIN LL, MASONIC K, HEIFFER MH, BREWER TG: The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. J. Pharm. Pharmacol. (1998) 50:173–182.
   PubMed Web of Science ®Google Scholar
• MAGGS JL, MADDEN S, BISHOP LP, O'NEILL PM, PARK BK: The rat biliary metabolites of dihydroartemisinin, an antimalarial endoperoxide. Drug Metabolism and Disposition (1997) 25:1200–1204.
   PubMed Web of Science ®Google Scholar
• FISHWICK J, EDWARDS G: The toxicity of artemisinin and related compounds on neuronal and glial cells in culture. Chemico-Biological Interact. (1995) 96:263–271.
   PubMed Web of Science ®Google Scholar
• WESCHE DL, DECOSTER MA, TORTELLA FC, BREWER TG: Neurotoxicity of artemisinin analogs in vitro. Antimi-crob. Agents Chemother. (1994) 38:1813–1819.
   PubMed Web of Science ®Google Scholar
• POSNER GH, PARKER MH, NORTHROP J et al.: Orally-active, hydrolytically stable, semisynthetic, antima-larial trioxanes in the artemisinin family. J. Med. Chem. (1999) 42 (2):300–304.
   PubMed Web of Science ®Google Scholar
• •Detailed report of the synthesis, stability and antimalarial properties of C-10 substituted artemisinin derivatives.
   Google Scholar
• POSNER GH, CUMMING JN, WOO S-H, PLOYPRADITH P,XIE S, SHAPIRO TA: Orally-active antimalarial 3-substituted trioxanes: new synthetic methodology and biological evaluation. J. Med. Chem. (1998) 41:940–951.
   PubMed Web of Science ®Google Scholar
• HALPAP B, NDJAVE M, PARIS M, BENAKIS A, KREMSNERPG: Plasma levels of artesunate and dihydroartemisi-nin in children with Plasmodium falciparum malaria in Gabon after administration of 50-milligram artesu-nate suppositories. Am. J. Trop. Med. Hyg. (1998) 58:365–368.
   PubMed Web of Science ®Google Scholar
• BRINGMANN G, FRANCOIS G, AKE ASSI L, SCHLAUER J: The alkaloids of Triphyophyllum peltatum (Dionco-phyllaceae). Chimia (1998) 52:18–28.
   Web of Science ®Google Scholar
• •Details the biological properties of the dioncophyllaceae alkaloid family.
   Google Scholar
• FRANCOIS G, TIMPERMAN G, ELING W, AKE ASSI LA, HOLENZ J, BRINGMANN G: Naphthylisoquinoline alkaloids against malaria: evaluation of the curative potentials of dioncophylline C and dioncopeltine A against Plasmodium berghei in vivo. Antimicrob. Agents Chemother. (1997) 41:2533–2539.
   PubMed Web of Science ®Google Scholar
• PLOWE CV, CORTESE JF, DJIMDE A et al.: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulphadoxine use and resistance. J. Infec. Dis. (1997) 176:1590–1596.
   PubMed Web of Science ®Google Scholar
• MCKIE JH, DOUGLAS KT, CHAN C, ROSER SA, YATES R, READ M: Rational drug design approach for overcoming drug resistance; application to pyrimeth-amine resistance in malaria. J. Med. Chem. (1998) 41:1367–1370.
   PubMed Web of Science ®Google Scholar
• ••Reports use of computer modelling to identify DHFR inhibi-tors active v pyrimethamine-resistant parasites.
   Google Scholar
• TOYODA T, BROBEY RKB, SANO G, HORIJ T, TOMIOKA N, ITAI A: Lead discovery of inhibitors of the dihydro-folate reductase domain of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Biochem. Biophys. Res. Commun. (1997) 235:515–519.
   PubMed Web of Science ®Google Scholar
• CABANTCHIK ZI, GLICKSTEIN H, GOLENSER J, LOYEVSKY M, TSAFACK A: Iron chelators: mode of action as antimalarials. Acta Haematol (1996) 95:70–77.
   PubMed Web of Science ®Google Scholar
• MABEZA GF, BIEMBA G, GORDEUK VR: Clinical studies of iron chelators in malaria. Acta Haematol. (1996) 95:78–86.
   PubMed Web of Science ®Google Scholar
• THUMA PE, OLIVIERI NF, MABEZA GF et al.: Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans. Am. J. Trop. Med. Hyg. (1998) 58:358–364.
   PubMed Web of Science ®Google Scholar
• WILSON RJM, DENNY PW, PREISER PR et al.: Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum. J. Mol. Biol. (1996) 261:155–172.
   PubMed Web of Science ®Google Scholar
• PICHERA ME, ROOS DS: A plastid organelle as a drug target in apicomplexan parasites. Nature (1997) 390:407–409.
   PubMed Web of Science ®Google Scholar
• ••Provides good evidence that the plastid organelle isrequired for parasite growth.
   Google Scholar
• RIDLEY RG: Planting new targets for antiparasitic drugs. Nature Med. (1998) 4:894–895.
   PubMed Web of Science ®Google Scholar
• •Summary of the potential to malaria chemotherapy of targeting the metabolic pathways of the plastid organelle.
   Google Scholar
• OHRT C, RICHIE TL, WIDJAJA H et al.: Mefloquine compared to doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomised, double-blind, placebo-controlled trial. Ann. Intern. Med. (1997) 126:963–972.
   PubMed Web of Science ®Google Scholar
• ANDERSEN SL, OLOO AJ, GORDON DM et al.: Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin. Infect. Dis. (1998) 26:146–150.
   PubMed Web of Science ®Google Scholar
• DUNNE MW, BOZZETTE S, MCCUTCHAN JA et al. Efficacy of azithromycin in prevention of Pneumo-cystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Lancet (1999) 354(9182):891–895.
   PubMed Web of Science ®Google Scholar
• DARKIN-RATTRAY SJ, GURNETT AM, MYERS RW et al: Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA (1996) 93(23):13143–13147.
   PubMed Web of Science ®Google Scholar
• ••Identification of a novel area for parasite chemotherapy.
   Google Scholar
• JOSHI MB, UN DT, CHIANG PH et al: Molecular cloning and nuclear localization of a histone deacetylase homologue in Plasmodium falciparum. Mol Biochem. Parasitol (1999) 99 (1) 11–19.
   PubMed Web of Science ®Google Scholar
• BERMAN J: Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. (1997) 24:684–703.
   PubMed Web of Science ®Google Scholar
• CROFT SL, NEAL RA, PENDERGAST W, CHAN JH: Activi-ties of alkylphosphorylcholines and related deriva-tives against Leishmania donovani. Biochem. Parasitol. (1987) 36:2633–2636.
   Google Scholar
• WHO article: Public/private partnership: developing an oral treatment for visceral leishmaniasis. TDR News (1999), No. 60 (October edition):1-2. (Also accessible via internet: http://www.whoint/tdr/).
   Google Scholar
• BURRI C, BODLEY AL, SHAPIRO TA: Topoisomerases in Kinetoplastids. Parasitol. Today (1996) 12 (6):226–231.
   PubMedGoogle Scholar
• •Highlights the potential of topoisomerases in kinetoplastids as targets for novel drugs.
   Google Scholar
• NENORTAS EC, BODLEY AL, SHAPIRO TA: DNA topoisomerases: a new twist for antiparasitic chemotherapy? Biochem. Biophys. Acta (1998) 1400:349–354.
   PubMed Web of Science ®Google Scholar
• ••Reviews the literature on inhibition of topoisomeraseactivity in parasitic protozoa.
   Google Scholar
• BODLEY AL, SHAPIRO TA: Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc. Natl. Acad. Sci. USA (1995) 92:3726–3730.
   PubMed Web of Science ®Google Scholar
• BODLEY AL, CUMMING JN, SHAPIRO TA: Effects of camptothecin, a topoisomerase I inhibitor, on Plasmodium falciparum. Biochem. Pharmacol (1998) 55:709–711.
   PubMed Web of Science ®Google Scholar
• NENORTAS E, BURRI C, SHAPIRO TA: Antitrypanosomal activity of fluoroquinolones. Antimicrob. Agents Chemother. (1999) 43:2066–2068.
   PubMed Web of Science ®Google Scholar
• HUDSON AT: Chemotherapy of Pneumocystis Carinii Pneumonia. Curr. Opin. Thar. Pat. (1991) 1 (3):289–302.
   Google Scholar
• WILKIN A, FEINBERG J: Pneumocystis carinii pneumonia: a clinical review. Am. Fam. Physician (1999) 60(6):1699–1708, 1713–1714.
   Google Scholar
• RAHMATHULLAH SM, HALL JE, BENDER BC, MCCURDY DR, TIDWELL RR, BOYKIN DW: Prodrugs for amidines: synthesis and antiPneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyfifuran. J. Med. Chem. (1999) 42(19):3994–4000.
   PubMed Web of Science ®Google Scholar
• •Synthesis of prodrugs of bis-amidines with promising anti-PCP activity.
   Google Scholar
• STECK EA, KINNAMON KK, DAVIDSON DE, DUXBURY AJ, JOHNSON AJ, MASTERS RE: Trypanosoma rhodesiense: evaluation of the action of 2,5-bis (4-guanyl-phenyfifuran. Exp. Parasitol. (1982) 53:133–144.
   PubMed Web of Science ®Google Scholar
• GROLL AH, WALSH TJ: Potential new antiftmgal agents. Curr. Opin. Infect. Dis. (1997) 10(6):449–458.
   Web of Science ®Google Scholar
• NABARRO DN, TAYLER EM: The 'roll back malaria' campaign. Science (1998) 280:2067–2068.
   PubMed Web of Science ®Google Scholar
• KAISER J: Raising the stakes in the race for new malaria drugs. Science (1998) 281:1930.
   PubMed Web of Science ®Google Scholar